BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, Haberkorn U, Dimitrakopoulou-strauss A. 18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma: Patterns of Tracer Uptake and Correlation With Bone Marrow Plasma Cell Infiltration Rate. Clinical Nuclear Medicine 2015;40:e300-7. [DOI: 10.1097/rlu.0000000000000773] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Alam MS, Fu L, Ren YY, Wu HB, Wang QS, Han YJ, Zhou WL, Li HS, Wang Z. 18F-FDG super bone marrow uptake: A highly potent indicator for the malignant infiltration. Medicine (Baltimore) 2016;95:e5579. [PMID: 28033252 DOI: 10.1097/MD.0000000000005579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ripani D, Caldarella C, Za T, Pizzuto DA, Rossi E, De Stefano V, Giordano A. Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation. Eur J Nucl Med Mol Imaging 2019;46:116-28. [PMID: 30054697 DOI: 10.1007/s00259-018-4108-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
3 Sachpekidis C, Merz M, Raab MS, Bertsch U, Weru V, Kopp-Schneider A, Jauch A, Goldschmidt H, Dimitrakopoulou-Strauss A. The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res 2021;11:100. [PMID: 34628525 DOI: 10.1186/s13550-021-00846-y] [Reference Citation Analysis]
4 Sachpekidis C, Hillengass J, Goldschmidt H, Wagner B, Haberkorn U, Kopka K, Dimitrakopoulou-Strauss A. Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Eur J Nucl Med Mol Imaging 2017;44:50-62. [PMID: 27573638 DOI: 10.1007/s00259-016-3502-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
5 Sachpekidis C, Dimitrakopoulou-Strauss A, Delorme S, Goldschmidt H. Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient. Diagnostics (Basel) 2017;7:E61. [PMID: 29244720 DOI: 10.3390/diagnostics7040061] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos M, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. The Lancet Oncology 2017;18:e206-17. [DOI: 10.1016/s1470-2045(17)30189-4] [Reference Citation Analysis]
7 Sachpekidis C, Kopp-Schneider A, Merz M, Jauch A, Raab MS, Goldschmidt H, Dimitrakopoulou-Strauss A. Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma? Cancers (Basel) 2020;12:E1335. [PMID: 32456181 DOI: 10.3390/cancers12051335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Sachpekidis C, Goldschmidt H, Dimitrakopoulou-Strauss A. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma. Molecules 2019;25:E134. [PMID: 31905752 DOI: 10.3390/molecules25010134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sachpekidis C, Merz M, Kopp-Schneider A, Jauch A, Raab MS, Sauer S, Hillengass J, Goldschmidt H, Dimitrakopoulou-Strauss A. Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma. Haematologica 2019;104:e420-3. [PMID: 30765474 DOI: 10.3324/haematol.2018.213041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Sachpekidis C, Türk M, Dimitrakopoulou-Strauss A. Quantitative, Dynamic 18F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report. Diagnostics (Basel) 2021;11:649. [PMID: 33916783 DOI: 10.3390/diagnostics11040649] [Reference Citation Analysis]
11 Zhou M, Chen Y, Liu J, Huang G. A predicting model of bone marrow malignant infiltration in 18F-FDG PET/CT images with increased diffuse bone marrow FDG uptake. J Cancer 2018;9:1737-44. [PMID: 29805699 DOI: 10.7150/jca.24836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Zuo X, Liu D. Progress in the application of minimal residual disease detection in multiple myeloma. J Hematopathol 2021;14:97-107. [DOI: 10.1007/s12308-020-00436-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]